Gables Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Gables Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-542	Closed	-$2K	–	349
2021 Q3	$2K	Hold	542	–	–	﹤0.01%	334
2021 Q2	$2K	Hold	542	–	–	﹤0.01%	333
2021 Q1	$5K	Hold	542	–	–	﹤0.01%	347
2020 Q4	$5K	Hold	542	–	–	﹤0.01%	330
2020 Q3	$2K	Buy	542 +417	+334%	+$2.21K	﹤0.01%	350
2020 Q2	$1K	Hold	125	–	–	﹤0.01%	345
2020 Q1	$0	Hold	125	–	–	﹤0.01%	417
2019 Q4	$1K	Hold	125	–	–	﹤0.01%	339
2019 Q3	$0	Hold	125	–	–	﹤0.01%	356
2019 Q2	$1K	Hold	125	–	–	﹤0.01%	329
2019 Q1	$1K	Hold	125	–	–	﹤0.01%	339
2018 Q4	$0	Buy	+125	New	+$393	﹤0.01%	372

Other funds holding DMAC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gables Capital Management's DMAC Position: Q4 2021 in Review

Gables Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q4 2021, closing a stake of 542 shares — an estimated $2K sold.

Gables Capital Management first reported a position in DMAC in Q4 2018 and held it in 12 quarters. The position peaked at $5K in Q1 2021. 39 funds tracked by Wall St. Rank hold DMAC as of Q4 2021.

Gables Capital Management reported no remaining DiaMedica Therapeutics position as of Q4 2021 after selling out during the quarter.
Gables Capital Management sold 542 DiaMedica Therapeutics shares in Q4 2021, an estimated $2K.
Gables Capital Management first reported a position in DiaMedica Therapeutics in Q4 2018 and held it in 12 quarters.
Gables Capital Management's DiaMedica Therapeutics position peaked at $5K in Q1 2021.
39 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2021.

Based on Gables Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.